NASDAQ: BBLGBone Biologics Corp Stock
$0.42-0.02 (-4.55%)
Updated Dec 8, 2023
BBLG Price
$0.42
Fair Value Price
$384.42
Market Cap
$1.32M
52 Week Low
$0.40
52 Week High
$13.20
P/E
-0.07x
P/B
0.35x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$6.51M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
-$9M
Beta
0.29
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BBLG Overview
Bone Biologics Corporation is a medical device company focused on bone regeneration in spinal fusion using recombinant human protein. The company's NELL-1/DBX product is an osteostimulative recombinant protein that provides target-specific control over bone regeneration. It is developing the NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease. The company was founded in 2004 and is headquartered in Burlington, MA.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BBLG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BBLG ($0.42) is undervalued by 99.89% relative to our estimate of its Fair Value price of $384.42 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BBLG ($0.42) is significantly undervalued by 99.89% relative to our estimate of its Fair Value price of $384.42 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BBLG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BBLG due diligence checks available for Premium users.
Be the first to know about important BBLG news, forecast changes, insider trades & much more!
BBLG News
Valuation
BBLG fair value
Fair Value of BBLG stock based on Discounted Cash Flow (DCF)
Price
$0.42
Fair Value
$384.42
Undervalued by
99.89%
BBLG ($0.42) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BBLG ($0.42) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BBLG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BBLG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
34.17x
Market
31.32x
BBLG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.35x
Industry
3.55x
BBLG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BBLG's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
BBLG's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.0M
Liabilities
$1.2M
Debt to equity
0.31
BBLG's short-term assets ($4.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BBLG's short-term assets ($4.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BBLG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BBLG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
$0.0
Financing
$0.0
BBLG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BBLG vs Medical Device Stocks
Bone Biologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.